Upstream Bio, Inc. (UPB): Price-to-Projected Revenue Ratio
Upstream Bio Inc (UPB) is developing advanced TSLP antibodies to combat dermatitis and asthma. This chart of the company's expected P/S ratio reflects valuation dynamics, with the metric currently at 54.40. The firm is currently deploying its post-IPO capital toward costly R&D research; however, the lack of sales and reliance on debt create significant risks in the event of potential clinical trial failures.
Comprehensive metric breakdowns and analytics for Upstream Pharma (UPB)
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt burden and liquidity indicators:
Debt to Equity Upstream Bio Inc|UPB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Upstream Bio Inc|UPB - Company Cumulative Debt|Debts to Book Capitalization Upstream Pharma|UPB - Company Long-Term Debts|Company Short-Term Debt Upstream Bio|Quick Liquidity Indicator upstreambio.com
- business earnings and investment ratios data:
UPB - Final Profit|Projected Future Earnings Upstream Bio Inc|UPB - Price to Earnings Ratio|Forward P/E Multiple Upstream Bio Corp|UPB - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Upstream Pharma|UPB - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Upstream Bio|UPB - Earnings per share for the trailing year|Quarterly EPS earnings growth upstreambio.com|UPB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Upstream Bio Inc
- sales volume and revenue indicators:
Initial company analysis:Upstream Bio UPB
The value of Upstream Bio Inc (UPB) is driven by the clinical success of verekimab and FDA approval. The estimated forward P/S ratio compares current market capitalization with expected future sales, measuring the premium for potential growth. This chart reflects the level of market optimism regarding the return on R&D expenditures. A decrease in the multiple confirms valuation resilience, whereas its growth increases risks in the event of any operational disruptions.
Competitors of Upstream Bio Inc
argenx - Forward Price-to-Revenue Multiple|Forward P/S Multiple BioNTech Inc. BNTX|ABVX - Price-to-Projected Revenue Ratio|Future Price to Revenue ADMA|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|IMVT - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple KNSA|GRFS (Grifols SA) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|CLDX (Celldex Corp) - Forward Price to Sales|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|biocryst.com (BCRX) - Market Cap to Future Revenue Ratio|Vera Therapeutics - Forward P/S Multiple|DNTH - Forward P/S Multiple|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple AbCellera Corp|Forward Price-to-Revenue Multiple TRML|PGEN: Forward Price to Sales|Forward P/S Multiple PHAR|Price-to-Projected Revenue Ratio NKTR (Nektar Therapeutics Inc)|Forward P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Market Cap to Expected Sales Ratio Immunome Bio (IMNM)|GOSS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio kalvista.com|SEPN (Septerna) - Forward Price-to-Revenue Multiple|Pieris Pharma - Forward Price to Sales|SVRA (Savara Corp) - Forward P/S Multiple|Rigel Corp (RIGL) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio AnaptysBio, Inc. (ANAB)|astriatx.com - Market Cap to Projected Revenue|Forward P/S Multiple ENGN (enGene)|RAPT - Forward Price-to-Revenue Multiple|JBIO: Forward Price-to-Revenue Multiple|ACRS - Forward P/S Multiple|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|Future Price to Revenue TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - Forward P/S Multiple|Price-to-Projected Revenue Ratio VTYX|Price-to-Projected Revenue Ratio Theratechnologies Inc (THTX)|AVTX: Future Price to Revenue|Forward P/S Multiple ELDN (Eledon Pharmaceuticals)|Forward Price to Sales AGEN|Climb Bio - Forward P/S Multiple|ZURA - Forward P/S Multiple|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Adagene Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio ImageneBio|Forward Price-to-Revenue Multiple Shattuck Therapeutics (STTK)|Forward P/S Multiple EQ|Forward P/S Multiple connectbiopharm.com (CNTB)|Immunic - Forward Price-to-Revenue Multiple|Forward Price to Sales ATRA|InflaRx GmbH - Forward P/S Multiple|Market Cap to Expected Sales Ratio x4pharma.com XFOR|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Celularity|Price-to-Projected Revenue Ratio INmune Bio Corp|Forward Price-to-Revenue Multiple Barinthus Biotherapeutics Corp (BRNS)|Forward Price-to-Revenue Multiple KZR (Kezar Life Sciences)|Forward P/S Multiple sabbiotherapeutics.com (SABS)|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|ENLV: Market Cap to Projected Revenue|Q32 Bio Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio GeoVax Corp|EDSA (Edesa Biotech, Inc.) - Forward Price-to-Revenue Multiple|ibioinc.com (IBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|XTL Biopharmaceuticals Ltd - Future Price to Revenue|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|Market Cap to Expected Sales Ratio hcwbiologics.com|Aptevo Therapeutics Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio AIM (AIM ImmunoTech, Inc.)|ADTX - Price-to-Projected Revenue Ratio|Forward Price to Sales GRI (GRI Bio Inc)|XRTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Vyome Therapeutics (HIND)|REVB (Revelation Biosciences) - Forward P/S Multiple|Forward P/S Multiple indaptusrx.com|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|Forward Price-to-Revenue Multiple calcimedica.com CALI|Affimed N.V. - Forward Price-to-Revenue Multiple|Forward Price to Sales ALLK|HOOKIPA - Forward P/S Multiple|IGMS: Price-to-Projected Revenue Ratio|ITOS: Forward P/S Multiple|OCEA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Market Cap to Future Revenue Ratio Third Harmonic Bio Inc THRD
